Smoking is the most dangerous cause of preventable death - killing 900,000 people in India every year. And here's good news for all those who can't stub the cigarette out of their lives. Pfizer has launched 'Champix', a smoking cessation therapy which works on a unique mechanism of action that reduces craving and smoking satisfaction. Champix is the first non-nicotine based prescription aid to be approved by US FDA in the last 10 years. Research shows that the odds of quitting smoking on Champix are twice that of buproprion and four times that of placebo. All Champix users can avail of the 'Champs Club' support program that together with the medication will help smokers desiring to quit, overcome their addiction. The 12-week Champix prescription course will be available across 17 cities in India. According to Dr Anjan Chatterjee, Medical Director, Pfizer Inc, "Champix offers a fresh opportunity to smokers in India who have previously failed quit attempts. The dearth of effective smoking cessation aids spurred our research teams at Pfizer to develop Champix and meet an unmet and urgent medical need." To support smokers who are considering quitting, Pfizer will partner with Smoking Cessation Clinics across India where smokers can seek counseling support, educational information about ill effects of smoking, tips and medical support to help them overcome their addiction.
